MACH7 TECHNOLOGIES LIMITED (M7T)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

M7T

M7T - MACH7 TECHNOLOGIES LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.95
Index:

Mach7 Technologies develops software platforms for the healthcare industry. It specialises in image management systems and patient data management. The company has been listed on the ASX since 2005.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.505

05 Dec
2025

0.010

OPEN

$0.50

2.02%

HIGH

$0.51

198,344

LOW

$0.49

TARGET
$0.76 50.5% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . IDX . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
M7T: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 2.6 - 2.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-2.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx33.8 M
Book Value Per Share xxxxxxxxxxxxxxx19.4
Net Operating Cash Flow xxxxxxxxxxxxxxx0.9 M
Net Profit Margin xxxxxxxxxxxxxxx-18.36 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-12.73 %
Return on Invested Capital xxxxxxxxxxxxxxx-12.47 %
Return on Assets xxxxxxxxxxxxxxx-9.04 %
Return on Equity xxxxxxxxxxxxxxx-12.73 %
Return on Total Capital xxxxxxxxxxxxxxx-16.87 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx0.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx4 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx23 M
Price To Book Value xxxxxxxxxxxxxxx1.70

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.7 M
Capex % of Sales xxxxxxxxxxxxxxx5.03 %
Cost of Goods Sold xxxxxxxxxxxxxxx36 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx7 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

01/12/2025

1

Buy

$0.76

50.50%

Management at Mach7 Technologies outlined a comprehensive strategic transformation at its AGM, centred on a customer-focused operating model, highlights Morgans.

The upcoming Flamingo AI platform will also aid the transformation, notes the broker, by modernising imaging workflows without requiring system replacement.

While FY26 revenue is expected to be softer and more second-half weighted due to fewer capital deals and lower services work, disciplined cost control supports resilience, suggest the analysts.

Longer-term benefits from the transformation are expected from higher recurring revenue and operating leverage.

Morgans retains a Buy rating and lowers its target to 76c from 81c.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.60 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

07/11/2025

1

Buy

$0.80

58.42%

Canaccord maintains a Buy rating on Mach7 Technologies with an 80c target, down from 85c, viewing 1Q26 as a reset period. It did, nonetheless, deliver a key milestone with the US Veterans’ Affairs Phase I contract going live after two years of delay.

The broker describes the deal as potentially transformative, likening it to Pro Medicus’ ((PME)) early US success with Sutter Health. Cost control remains solid, cash stood at $18.9m, and operating expenses are covered 75% by recurring revenue, highlight the analysts.

While the broker's FY26 and FY27 revenue forecasts are lowered by -12% and -18%, respectively, Canaccord sees significant upside if Phase II proceeds.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Extra Coverage Research History >

M7T STOCK CHART

FNArena News on M7T

1
Australian Broker Call *Extra* Edition – Nov 12, 2025

Nov 12 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Oct 07, 2025

Oct 07 2025 - Daily Market Reports
3
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Sep 04, 2025

Sep 04 2025 - Daily Market Reports
5
FNArena Corporate Results Monitor – 28-08-2025

Aug 28 2025 - Australia

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps